---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-014115"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2023-04-24T23:59:59+00:00"
generated_at: "2026-06-16T20:50:04.249454+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ARCA biopharma reports Q1 net loss of $1.3M; strategic review ongoing

## Summary
- Net loss of $1.3M ($0.09 per share) vs $3.3M ($0.23) in Q1 2022; improvement due to lower R&D costs.
- Cash and equivalents $40.9M as of March 31, 2023, expected to fund operations through mid-2024.
- Strategic review process continues with Ladenburg Thalmann; evaluating merger, asset sale, or other options.
- R&D expenses fell to $0.4M from $2.2M YoY after enrollment completion in rNAPc2 Phase 2b trial.
- G&A expenses rose to $1.4M from $1.1M, including $159K severance for former General Counsel.

## SEC filing metadata
- accession: 0000950170-23-014115
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2023-04-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000095017023014115/0000950170-23-014115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000095017023014115/abio-20230424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-014115
- JSON: https://secwatch.observer/filing/0000950170-23-014115.json
- Plain text: https://secwatch.observer/filing/0000950170-23-014115.txt

## Key facts
- Earnings Releases
  Oruka Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income $1.3 million, EPS $0.09 per basic and diluted share.
  - Period: the quarter ended March 31, 2023
  - Net income: $1.3 million
  - EPS: $0.09 per basic and diluted share
  - Result: reported results
  source text: Net loss for the quarter ended March 31, 2023 was $1.3 million, or $0.09 per basic and diluted share, compared to $3.3 million, or $0.23 per basic and diluted share in the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/907654/000095017023014115/0000950170-23-014115-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.